NGM·Healthcare·$1.4B·#215 / 520 in Healthcare
NNNN Anbio Biotechnology
50SPECULATIVE
CATEGORY BREAKDOWN
GROWTH9
QUALITY100
STABILITY48
VALUATION0
GOVERNANCE59
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+5.6%
9
> 50% strong
Gross Margin
Revenue retained after direct costs
87.2%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
14 months
48
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
N/A
50
< 25% strong
Price / Sales
Market cap relative to trailing revenue
156.3x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
72
100
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
4.8%
38
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+0.0%
100
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE NNNN WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when NNNN's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.